new coins in the market Top stories

Wuzhou Spring today bought 101 million yuan and sold 140 million yuan on Shanghai Stock Connect. Wuzhou Spring today traded at a daily limit, with a turnover of 4.335 billion yuan and a turnover rate of 35.76%. After-hours data showed that Ningbo Sangtian Road mat bought 77.1945 million yuan, and Shanghai Stock Connect special seats bought 101 million yuan and sold 140 million yuan.Hite Bio: Two drugs are planned to be selected for national centralized drug procurement. Hite Bio announced that the company participated in the tenth batch of national centralized drug procurement. According to the selected results released by the joint procurement, roxatidine acetate hydrochloride and pentoxifylline injection for injection of the company are selected for this centralized procurement. These two drugs are suitable for the treatment of upper gastrointestinal bleeding and peripheral arterial diseases respectively. The procurement cycle is from the date of implementation of the selected results to December 31, 2027, during which medical institutions will give priority to the use of selected drugs. The company obtained the Drug Registration Certificate of the above drugs in 2024, but it has not generated sales revenue this year. This election will help to enhance the brand influence of the company and have a positive impact on the company's development.Qinchuan Machine Tool: The company's machine tool business section can provide a variety of processing equipment for humanoid robot manufacturers. Qinchuan Machine Tool said on the interactive platform that the company's machine tool business section can provide a variety of processing equipment for humanoid robot manufacturers, such as gear grinder, planetary roller screw pair key processing equipment thread grinder, etc. The spare parts business section of the company has the foundation of R&D and manufacturing of planetary roller screw by-products. Now, it has gradually started small batch production and verified its application. In the future, according to the market demand, it will gradually improve the detection and processing means and build its capacity.

From January to October, the total output of lithium batteries in China increased by 16% year-on-year. According to the Ministry of Industry and Information Technology, China's lithium-ion battery industry continued to grow from January to October 2024. According to the announcement of lithium battery industry norms, enterprise information and industry associations, the total output of lithium batteries in China from January to October was 890GWh, up 16% year-on-year. According to the data of the National Bureau of Statistics, the profit of China's lithium battery manufacturing industry increased by 39.4% from January to October. In the battery sector, the output of energy storage lithium batteries exceeded 200GWh from January to October. The loading capacity of power lithium batteries for new energy vehicles is about 405GWh. From January to October, the total export of lithium batteries in China reached 350.2 billion yuan, down 9.2% year-on-year, and the decline was 3.3 percentage points narrower than that in January-June.Fat Donglai is working out stricter measures to solve the problem of purchasing, including real-name purchase and regular quantitative purchase system. On December 13th, Yu Donglai issued a document saying: Fat Donglai is working out stricter and more effective measures! In the future, including real-name purchase and regular quantitative purchase system! Discuss and formulate relevant systems to control purchasing behavior and lift the membership of permanent fat east!Hite Bio: Two drugs are planned to be selected for national centralized drug procurement. Hite Bio announced that the company participated in the tenth batch of national centralized drug procurement. According to the selected results released by the joint procurement, roxatidine acetate hydrochloride and pentoxifylline injection for injection of the company are selected for this centralized procurement. These two drugs are suitable for the treatment of upper gastrointestinal bleeding and peripheral arterial diseases respectively. The procurement cycle is from the date of implementation of the selected results to December 31, 2027, during which medical institutions will give priority to the use of selected drugs. The company obtained the Drug Registration Certificate of the above drugs in 2024, but it has not generated sales revenue this year. This election will help to enhance the brand influence of the company and have a positive impact on the company's development.

Li Dongsheng said that low-price competition has no way out, and it will only get involved. On December 11th, at TCL Global Innovation Conference, founder Li Dongsheng said that in the current market competition, low-price competition has no way out, and it will only get involved in endless "involution". To surpass its competitors, it is necessary to strive for more breakthroughs in high-end products. He Jun, vice president of TCL Industry, talked about the current development of industrial software enterprises in China in a subsequent interview. He also said that from the aspects of financing environment and market support for enterprises, China is not an environment where good software enterprises can be born at present, but in the long run, industrial software may make a breakthrough in China software, and this time will not be very fast, and it will not be seen for three or five years.The organization looks forward to the semiconductor industry in 2025: the AI ​ ​ replacement tide leads the growth, and the semiconductor ETF(512480) may usher in new development opportunities. On December 13, the semiconductor ETF(512480) closed down by 1.38%, with a turnover of 1.671 billion yuan. The constituent stocks are mixed, and Zhaoyi Innovation leads the rise. In terms of decline, SMIC led the decline. CICC said that after the boom in 2024, it is expected that the inventory of the semiconductor industry will stabilize and the relationship between supply and demand will be more balanced in 2025. With the gradual landing of AI cloud and end demand, domestic semiconductor elements will usher in new development opportunities. In addition, the AI-changing tide has a pulling effect on the downstream demand of the semiconductor design sector, which is expected to accelerate the growth of the semiconductor design sector in 2025 and inject new vitality into the industry.Zhendong Pharmaceutical has set up a new health management service company. The enterprise search APP shows that recently, Shanxi Zhendong Health Management Service Co., Ltd. was established, with Zhao Jin as the legal representative and a registered capital of 10 million yuan. Its business scope includes: remote health management services; Health consulting services (excluding medical services), etc. Enterprise investigation shows that the company is wholly owned by Zhendong Pharmaceutical.